Related Experiment Video
Updated: May 29, 2025
06:15
Tumor Treating Field Therapy in Combination with Bevacizumab for the Treatment of Recurrent Glioblastoma
Published on: October 27, 2014
27.1K
Temozolomide as neoadjuvant therapy for bladder paraganglioma
Yi Liu1, Congwei Jia2, Zhan Wang1
1Department of Urology, Peking Union Medical College Hospital, Chinese Academy of Medical Sciences and Peking Union Medical College, Beijing, China.
Endocrine
|February 7, 2025
Summary
Bladder paraganglioma (BPG), a rare tumor, was successfully treated with neoadjuvant temozolomide to shrink the mass before surgical removal. This approach enabled a less invasive partial cystectomy for a large BPG.
Area of Science:
- Urology
- Oncology
- Endocrinology
Background:
- Bladder paraganglioma (BPG) is a rare subtype of pheochromocytoma and paraganglioma (PPGL).
- Common symptoms include hypertension during urination, headache, dizziness, palpitations, and hematuria.
- Surgical resection is the primary treatment for BPG.
Observation:
- A male patient presented with hypogastralgia and hematuria, diagnosed with BPG.
- The tumor was too large for immediate partial cystectomy.
- The patient was referred for further management.
Findings:
- Neoadjuvant therapy with temozolomide was administered to reduce tumor size.
- Seven cycles of temozolomide led to significant tumor shrinkage.
- The reduced tumor size allowed for successful partial cystectomy.
Implications:
- Temozolomide can be an effective neoadjuvant treatment for large bladder paragangliomas.
- This strategy may improve surgical outcomes and allow for less invasive procedures.
- Highlights the importance of multidisciplinary care for rare tumors.
